Interleukin-2 (IL-2) Mutein Therapies Market Report 2026

The interleukin-2 (il-2) mutein therapies market size has grown rapidly in recent years. It will grow from $0.73 billion in 2025 to $0.84 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to advancements in cytokine engineering techniques, increasing understanding of immune signaling pathways, early clinical success of modified IL-2 therapies, rising investment in immuno-oncology research, growing prevalence of immune-mediated diseases.

The interleukin-2 (il-2) mutein therapies market size is expected to see rapid growth in the next few years. It will grow to $1.43 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of personalized immunotherapy approaches, increasing clinical trial activity for next-generation cytokines, rising demand for safer immune modulators, growing regulatory support for innovative biologics, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include increasing development of receptor-biased il-2 muteins, rising focus on reduced cytokine toxicity profiles, growing use of combination immunotherapy regimens, expansion of precision immune modulation approaches, enhanced clinical pipeline activity for autoimmune and oncology indications.

The growing demand for targeted immunotherapies is expected to drive the expansion of the interleukin-2 (IL-2) mutein therapies market. Targeted immunotherapies are treatments developed to modulate the immune system in a way that selectively attacks cancer cells while limiting damage to healthy tissues. Demand for these therapies is increasing as healthcare providers and researchers pursue safer and more effective alternatives to conventional chemotherapy and radiation therapy, which are often associated with high toxicity and limited specificity. IL-2 mutein therapies advance targeted immunotherapies by using engineered variants of interleukin-2 that selectively activate immune effector cells involved in anti-tumor responses while minimizing activation of pathways linked to systemic toxicity. For instance, in April 2025, according to the Cancer Research Institute, a US-based non-profit organization, FDA approvals included 17 new targeted immunotherapy agents in 2024, broadening treatment options for immune-based cancer therapies and expanding the patient population that can benefit from such treatments. Therefore, the increasing demand for targeted immunotherapies is fueling the growth of the interleukin-2 (IL-2) mutein therapies market.

Key companies operating in the interleukin-2 (IL-2) mutein therapies market are increasingly focusing on technological advancements in cytokine-based immunotherapy, such as selective regulatory T-cell (Treg) activation through engineered IL-2 muteins. Selective regulatory T-cell activation via engineered IL-2 muteins involves the use of genetically modified IL-2 proteins designed to preferentially stimulate Tregs while limiting activation of effector immune cells. For example, in December 2023, Almirall S.A., a Spain-based pharmaceutical company, initiated the first Phase I clinical study of its engineered IL-2 mutein fusion protein, ALM223, to evaluate safety, pharmacokinetics, immunogenicity, and pharmacodynamics in autoimmune diseases. The candidate features selective Treg activation, a modified Fc fusion to improve molecular stability, and an engineered cytokine backbone to optimize immune modulation. While these technological advances highlight the promise of IL-2 muteins in achieving targeted immunomodulation and broader autoimmune applicability, their clinical efficacy and long-term safety profiles remain to be established through ongoing and future trials.

In January 2025, Asher Biotherapeutics Inc., a US-based biotechnology company developing and owning IL-2 mutein therapeutics, entered into a partnership with Amgen Inc. to evaluate etakafusp alfa in combination with IMDELLTRA in a Phase 1b clinical trial for extensive-stage small cell lung cancer (ES-SCLC). Through this partnership, the companies aim to progress the clinical development of etakafusp alfa by evaluating its potential to enhance T cell-mediated anti-tumor activity when administered alongside IMDELLTRA in patients with ES-SCLC. Amgen Inc. is a US-based biotechnology company that develops and commercializes innovative therapies across oncology and other therapeutic areas.

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Tariffs are impacting the interleukin-2 mutein therapies market by increasing costs associated with imported biologic manufacturing inputs, specialized reagents, single-use bioprocessing equipment, and cold-chain logistics infrastructure. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on globally sourced raw materials and advanced production technologies, while Asia-Pacific faces higher costs for export-oriented biologics manufacturing. These tariffs are raising development and production expenses and extending commercialization timelines. However, they are also encouraging domestic biologics manufacturing capacity, regional supply chain localization, and long-term investments in local bioprocessing infrastructure.

The interleukin-2 (il-2) mutein therapies market research report is one of a series of new reports that provides interleukin-2 (il-2) mutein therapies market statistics, including interleukin-2 (il-2) mutein therapies industry global market size, regional shares, competitors with a interleukin-2 (il-2) mutein therapies market share, detailed interleukin-2 (il-2) mutein therapies market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin-2 (il-2) mutein therapies industry. This interleukin-2 (il-2) mutein therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interleukin-2 (IL-2) mutein therapies refer to engineered variants of the natural IL-2 cytokine that have been structurally altered to selectively modify receptor binding and immune cell activation. These therapies are designed to improve therapeutic efficacy and safety by preferentially stimulating specific immune cell populations, such as regulatory T cells or effector T cells, while minimizing toxicity.

The primary product types of interleukin-2 (IL-2) mutein therapies include monotherapy and combination therapy. Monotherapy refers to treatment approaches in which IL-2 muteins are administered independently to regulate immune responses for therapeutic benefit. These therapies are delivered through routes such as intravenous, subcutaneous, and other administration methods. They are applied across indications including cancer, autoimmune disorders, infectious diseases, and other applications, and are used by end users including hospitals, specialty clinics, research institutions, and other end users.

The interleukin-2 (IL-2) mutein therapies market consists of sales of efavaleukin alfa, rezpegaldesleukin, bempegaldesleukin, nemvaleukin alfa.Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.